Our recent studies demonstrated that the inhibition of MCT1, MCT4, or their chaperone CD147 impairs leukemia cell proliferation, and pointed to CD147 and MCT4 as potential therapeutic targets in AML. This evidence concerns the gene BSG and leukemia.